ClinicalTrials.gg
CompletedNCT00998946Updated Nov 5, 2021Results posted

Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 2 interventional study of Pralatrexate and Vitamin B12 in Lymphoma, B-Cell, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 90 open to participants now, 156 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
225th of 380
29 · median 37
Started
2009
with 9 others
Phase 2
112 of 398
22 open now
Registered
72nd of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 225th largest by enrollment of the 380 interventional ones that give a count, is one of 10 that started in 2009, is one of 112 in phase 2, and was the 72nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

90 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma (NHL). The study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in this participant population. Additionally, this study includes the collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this participant population (PK is the activity of a drug in the body over a period of time, including how the drug is absorbed, distributed in the body, localized in the tissues, and excreted from the body).

03

Conditions studied

  • Lymphoma, B-Cell

Keywords

  • Relapsed
  • Refractory
  • Non-Hodgkin's
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed, measurable (lesion or node =2 cm by CT [at least 1 cm if by spiral CT]) B-cell Non-Hodgkin's Lymphoma, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification
  • Progressive or persistent disease after ≥ 1 prior treatment(s)
  • Recovered from toxic effects of prior treatment
  • At least 4 weeks since most recent cytotoxic therapy
  • Easter Cooperative Oncology Group () performance status ≤ 2
  • Adequate blood, liver, and kidney functions as defined by laboratory levels
  • 1.0 mg/day orally of folic acid for at least 7 days prior \& 1 mg intramuscular of vitamin B12 within 10 weeks of the planned start of pralatrexate
  • Females of must agree to use medically acceptable from start of pralatrexate until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment
  • Males who are not surgically sterile must agree to use medically acceptable birth control from start of pralatrexate until at least 90 days after the last administration of pralatrexate
  • Available for repeat dosing and follow-up
  • Able to give written

Exclusion criteria

Exclusion Criteria:

  • participants with diffuse large B-cell lymphoma (DLBCL) who are candidates for high-dose therapy and stem cell transplantation (SCT) and for whom high-dose therapy and autologous SCT is a standard curative option
  • Active concurrent (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancies other than those exceptions listed above, the participant must be disease-free for ≥ 5 years. Participants with other prior malignancies \< 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease
  • Congestive heart failure Class III/IV according to the Functional Classification
  • Uncontrolled hypertension
  • Known (HIV)-positive diagnosis
  • Symptomatic central nervous system (CNS) or lesions for which treatment is required. Participants who received prophylactic CNS treatment are eligible.
  • Participants who have undergone an allogeneic SCT
  • Participants who have relapsed \< 100 days from the time of an autologous SCT
  • Participants with disease refractory to peripheral blood SCT or who have relapsed \< 100 days from the time of transplant
  • Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the participant to receive protocol treatment.
  • Major surgery within 14 days of enrollment
  • Receipt of any conventional chemotherapy or radiation therapy (encompassing a substantial [> 10%] amount of bone marrow) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study
  • Receipt of systemic within 1 week of study treatment, unless participant has been taking a continuous dose of no more than 10 mg/day of prednisone or its equivalent for at least 1 month
  • Use of any drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study
  • Previous exposure to pralatrexate
  • Females who are pregnant or breastfeeding
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Pralatrexate

    Participants received pralatrexate at an initial dose of 30 mg/m\^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m\^2 may be reduced to 20 mg/m\^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m\^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done. Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate.

    Drug: Pralatrexate · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Pralatrexate injection administered as intravenous (IV) push

    Also known as: FOLOTYN, PDX, (RS)-10-propargyl-10-deazaaminopterin

  • Dietary supplementVitamin B12

    1 mg intramuscular (IM) injection

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    Oral 1 mg tablet

    Also known as: Vitamin B9, Folate, Folacin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR). Tumor response was evaluated on the basis of clinical and radiological criteria, assessed according to International Workshop Criteria (IWC) with or without positron emission tomography (PET) scans. Per IWC criteria CR is defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to non-Hodgkin's lymphoma (NHL) and PR is defined as \>= 50% decrease in sum of the product of the perpendicular diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in size of other nodes, liver or spleen.

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response (DOR)

    The Duration of Response was defined as the time (in months) from the date the measurement criteria were first met for CR or PR (whichever status was recorded first) until the first subsequent date that relapse or progression was documented. It was assessed according to IWC with or without PET, subject to its availability. Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.

    Time frame: Up to 24 months

  2. Progression Free Survival (PFS)

    Progression-free survival (PFS) was the duration of time (in months) from first administration of study treatment to date of first documented progression or death from any cause. It was based on tumor assessments made according to the IWC with or without PET scans, subject to their availability. Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.

    Time frame: Up to 24 months

  3. Overall Survival (OS)

    Overall Survival was the time (in months) from first administration of study treatment until the date of death.

    Time frame: Up to 24 months

07

Results

Posted Nov 5, 2021

Participant flow

Participant flow — Overall Study
MilestonePralatrexate
Started29
Safety population27
Completed20
Not completed9
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1
Withdrew: Death2
Withdrew: Reason unspecified3
Withdrew: Enrolled but not dosed2

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR). Tumor response was evaluated on the basis of clinical and radiological criteria, assessed according to International Workshop Criteria (IWC) with or without positron emission tomography (PET) scans. Per IWC criteria CR is defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities definitely assignable to non-Hodgkin's lymphoma (NHL) and PR is defined as \>= 50% decrease in sum of the product of the perpendicular diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in size of other nodes, liver or spleen.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsPralatrexate
Objective Response Rate (ORR)4 (0 to 19)
SecondaryDuration of Response (DOR)

The Duration of Response was defined as the time (in months) from the date the measurement criteria were first met for CR or PR (whichever status was recorded first) until the first subsequent date that relapse or progression was documented. It was assessed according to IWC with or without PET, subject to its availability. Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.

Time frame:
Up to 24 months
Reported as:
Median · months
Duration of Response (DOR)
monthsPralatrexate
Duration of Response (DOR)NA (NA to NA)
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS) was the duration of time (in months) from first administration of study treatment to date of first documented progression or death from any cause. It was based on tumor assessments made according to the IWC with or without PET scans, subject to their availability. Per IWC, progression was defined as a ≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions.

Time frame:
Up to 24 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPralatrexate
Progression Free Survival (PFS)3.6 (1.9 to 3.7)
SecondaryOverall Survival (OS)

Overall Survival was the time (in months) from first administration of study treatment until the date of death.

Time frame:
Up to 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsPralatrexate
Overall Survival (OS)NA (7.4 to NA)

Adverse events

Collected over Up to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pralatrexate11/27 (40.7%)11/27 (40.7%)27/27 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPralatrexate
StomatitisGastrointestinal disorders5/27
PyrexiaGeneral disorders2/27
PneumoniaInfections and infestations2/27
Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/27
Febrile NeutropeniaBlood and lymphatic system disorders1/27
NeutopeniaBlood and lymphatic system disorders1/27
Atrial fibrillationCardiac disorders1/27
Cardiac Failure CongestiveCardiac disorders1/27
Ear PainEar and labyrinth disorders1/27
DiarrhoeaGastrointestinal disorders1/27
Most frequent other events
Showing 10 of 146
Most frequent other events
EventPralatrexate
FatigueGeneral disorders21/27
StomatitisGastrointestinal disorders16/27
ThrombocytopeniaBlood and lymphatic system disorders13/27
NauseaGastrointestinal disorders12/27
AnaemiaBlood and lymphatic system disorders11/27
NeutropeniaBlood and lymphatic system disorders7/27
ConsitpationGastrointestinal disorders7/27
DiarrhoeaGastrointestinal disorders7/27
PyrexiaGeneral disorders7/27
Abdominal painGastrointestinal disorders6/27

Baseline characteristics

Safety Population included all participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Pralatrexate
Mean64.8 ± 14.07
Sex: Female, Male
Sex: Female, Male(Participants)Pralatrexate
Female7
Male20
08

Study locations

11 sites
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Kootenai Cancer Center
    Post Falls, Idaho 83854, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Owsley Brown Frazier Cancer Center
    Louisville, Kentucky 40245, United States
  • Overton Brooks VA Medical Center
    Shreveport, Louisiana 71101, United States
  • Frontier Cancer Center and Blood Institute
    Billings, Montana 59102, United States
  • New York University Hospital
    New York, New York 10016, United States
  • Providence Cancer Center
    Portland, Oregon 97225, United States
  • The West Clinic (ACORN)
    Memphis, Tennessee 38120, United States
  • Gundersen Lutheran
    La Crosse, Wisconsin 54601, United States
  • University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center
    Madison, Wisconsin 53705-2275, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Aug 2012, 35 months.

Results were first posted in Nov 2021, 9 years 3 months after primary completion.

Of 121 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2009
First posted
Oct 21, 2009
StartActual
Sep 2009
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Nov 5, 2021
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00998946
Responsible party
Sponsor
First posted
Oct 21, 2009
Start date
Sep 2009
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Nov 5, 2021
Last update
Nov 5, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion